JP7783688B2 - 免疫調節剤の結晶形 - Google Patents

免疫調節剤の結晶形

Info

Publication number
JP7783688B2
JP7783688B2 JP2020517332A JP2020517332A JP7783688B2 JP 7783688 B2 JP7783688 B2 JP 7783688B2 JP 2020517332 A JP2020517332 A JP 2020517332A JP 2020517332 A JP2020517332 A JP 2020517332A JP 7783688 B2 JP7783688 B2 JP 7783688B2
Authority
JP
Japan
Prior art keywords
formula
compound
cancer
solvent
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501127A (ja
JP2021501127A5 (https=
Inventor
ユー，シュー
Original Assignee
キュリス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュリス，インコーポレイテッド filed Critical キュリス，インコーポレイテッド
Publication of JP2021501127A publication Critical patent/JP2021501127A/ja
Publication of JP2021501127A5 publication Critical patent/JP2021501127A5/ja
Priority to JP2023108094A priority Critical patent/JP2023134541A/ja
Application granted granted Critical
Publication of JP7783688B2 publication Critical patent/JP7783688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020517332A 2017-09-29 2018-09-27 免疫調節剤の結晶形 Active JP7783688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023108094A JP2023134541A (ja) 2017-09-29 2023-06-30 免疫調節剤の結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/104485 2017-09-29
PCT/CN2017/104485 WO2019061324A1 (en) 2017-09-29 2017-09-29 CRYSTALLINE FORMS OF IMMUNOMODULATORS
PCT/US2018/053052 WO2019067678A1 (en) 2017-09-29 2018-09-27 CRYSTALLINE FORMS OF IMMUNOMODULATORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023108094A Division JP2023134541A (ja) 2017-09-29 2023-06-30 免疫調節剤の結晶形

Publications (3)

Publication Number Publication Date
JP2021501127A JP2021501127A (ja) 2021-01-14
JP2021501127A5 JP2021501127A5 (https=) 2021-11-04
JP7783688B2 true JP7783688B2 (ja) 2025-12-10

Family

ID=65900346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517332A Active JP7783688B2 (ja) 2017-09-29 2018-09-27 免疫調節剤の結晶形
JP2023108094A Pending JP2023134541A (ja) 2017-09-29 2023-06-30 免疫調節剤の結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023108094A Pending JP2023134541A (ja) 2017-09-29 2023-06-30 免疫調節剤の結晶形

Country Status (14)

Country Link
US (5) US11040948B2 (https=)
EP (1) EP3687534A4 (https=)
JP (2) JP7783688B2 (https=)
KR (2) KR20240115921A (https=)
CN (2) CN111163772A (https=)
AU (2) AU2018341583B2 (https=)
BR (1) BR112020006137A2 (https=)
CA (1) CA3076013A1 (https=)
EA (1) EA202090500A1 (https=)
IL (2) IL315814A (https=)
MY (1) MY201378A (https=)
PH (1) PH12020550133A1 (https=)
SG (1) SG11202002378XA (https=)
WO (2) WO2019061324A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023134541A (ja) * 2017-09-29 2023-09-27 キュリス，インコーポレイテッド 免疫調節剤の結晶形

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
EP3694841A1 (en) 2017-10-11 2020-08-19 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
MY206121A (en) 2017-11-03 2024-11-29 Aurigene Discovery Tech Ltd Dual inhibitors of tim-3 and pd-1 pathways
AU2018360389B2 (en) 2017-11-06 2024-09-19 Aurigene Oncology Limited Conjoint therapies for immunomodulation
SG11202106250RA (en) 2018-12-20 2021-07-29 Impact Selector International Llc Downhole tool for connecting with a conveyance line

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227725A (en) 1962-04-17 1966-01-04 Union Carbide Corp Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
TW201311B (https=) 1991-06-17 1993-03-01 Hoffmann La Roche
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
WO2002079499A1 (en) 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
EP1888512A2 (en) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
US20090042926A1 (en) 2005-12-20 2009-02-12 Jason Imbriglio Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
CN101484433A (zh) 2006-02-15 2009-07-15 艾博特公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
PL2076501T3 (pl) * 2006-09-25 2016-06-30 Ptc Therapeutics Inc Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2009006555A2 (en) 2007-07-02 2009-01-08 Yu, Ming Methods, composition, targets for combinational cancer treatments
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
EA018551B1 (ru) 2008-02-22 2013-08-30 Айрм Ллк ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
JP2012507563A (ja) 2008-10-30 2012-03-29 エリクシアー ファーマシューティカルズ， インコーポレイテッド スルホンアミド含有化合物およびその使用
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011137587A1 (en) 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012129564A2 (en) 2011-03-24 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome chymotrypsin-like inhibition using pi-1833 analogs
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
EA029661B1 (ru) * 2013-09-06 2018-04-30 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
GB2516515B8 (en) 2013-12-04 2016-10-05 Intelligent Growth Solutions Ltd Automated arrangement to grow plants under lighting in a vertical tower
US10174012B2 (en) * 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
BR112017019304A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
EA201791629A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
AU2017345500B2 (en) 2016-10-20 2022-03-10 Aurigene Oncology Limited Dual inhibitors of vista and PD-1 pathways
WO2019061324A1 (en) * 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
EP3694841A1 (en) 2017-10-11 2020-08-19 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
MY206121A (en) 2017-11-03 2024-11-29 Aurigene Discovery Tech Ltd Dual inhibitors of tim-3 and pd-1 pathways
AU2018360389B2 (en) 2017-11-06 2024-09-19 Aurigene Oncology Limited Conjoint therapies for immunomodulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023134541A (ja) * 2017-09-29 2023-09-27 キュリス，インコーポレイテッド 免疫調節剤の結晶形

Also Published As

Publication number Publication date
EP3687534A1 (en) 2020-08-05
PH12020550133A1 (en) 2021-02-08
SG11202002378XA (en) 2020-04-29
US20200247766A1 (en) 2020-08-06
JP2021501127A (ja) 2021-01-14
US11040948B2 (en) 2021-06-22
IL315814A (en) 2024-11-01
US12252475B2 (en) 2025-03-18
EP3687534A4 (en) 2021-06-30
AU2024201938A1 (en) 2024-04-11
KR20240115921A (ko) 2024-07-26
AU2018341583A1 (en) 2020-04-02
US20250188045A1 (en) 2025-06-12
IL273463A (en) 2020-05-31
CA3076013A1 (en) 2019-04-04
JP2023134541A (ja) 2023-09-27
US11939306B2 (en) 2024-03-26
CN117209444A (zh) 2023-12-12
US20240182433A1 (en) 2024-06-06
WO2019067678A1 (en) 2019-04-04
US20210380544A1 (en) 2021-12-09
WO2019061324A1 (en) 2019-04-04
AU2018341583B2 (en) 2024-04-04
EA202090500A1 (ru) 2020-11-03
KR20200060402A (ko) 2020-05-29
BR112020006137A2 (pt) 2020-10-13
US20230167077A1 (en) 2023-06-01
US11643401B2 (en) 2023-05-09
CN111163772A (zh) 2020-05-15
MY201378A (en) 2024-02-21

Similar Documents

Publication Publication Date Title
JP7783688B2 (ja) 免疫調節剤の結晶形
US12187689B2 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
HK40103034A (zh) 免疫调节剂的晶体形式
HK40024522A (en) Crystal forms of immunomodulators
EA048760B1 (ru) Кристаллические формы иммуномодуляторов
EA041875B1 (ru) Кристаллические формы 3-замещенного 1,2,4-оксадиазола

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20200826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200826

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230710

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251128

R150 Certificate of patent or registration of utility model

Ref document number: 7783688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150